Design and Fabrication of Ordered Mesoporous Alumina Scaffold for Drug Delivery of Poorly Water Soluble Drug

Research Article

Austin Therapeutics. 2015; 2(1): 1015.

Design and Fabrication of Ordered Mesoporous Alumina Scaffold for Drug Delivery of Poorly Water Soluble Drug

Borbane SA, Pande VV*, Vibhute SK, Kendre PN and Dange VU

Department of Pharmaceutics, Sanjivani College of Pharmaceutical Education and Research, India

*Corresponding author: Pande VV, Department of Pharmaceutics, Sanjivani College of Pharmaceutical Education and Research, India

Received: February 26, 2014; Accepted: September 04, 2015; Published: September 06, 2015

Abstract

The aim of present study was to develop and evaluate Telmisartan (TEL) loaded Ordered Mesoporous Alumina (OMA) scaffold for enhanced solubility and dissolution of TEL. The Ordered Mesoporous Alumina acts as a carrier for drug and increases its solubility and dissolution rate. The OMA was synthesized by Evaporation Induced Self Assembly (EISA) mechanism and characterized by the FT-IR, SEM, TEM porosimetry and XRD. The total specific surface area on OMA was found to be 299 m²/g whereas total cumulative volume, average pore diameter and total porosity was found to be 1.3182 cc/g, 26 nm and 23% respectively. The Telmisartan (TEL) was loaded in the OMA by the Solvent Impregnation Method. The TEL: OMA compatibility was studied by FT-IR spectroscopy; where no significant interaction was observed. The drug loading was confirmed by UV and TGA; which was found to be 45% and 43% respectively. Finally the dissolution rate and drug release of TEL loaded OMA was compared to the pure crystalline Telmisartan. Significant increase in dissolution and drug release from OMA was observed. It is concluded that the OMA could be a promising drug carrier and platform for delivery of poorly water soluble drugs for improved oral bioavailability.

Keywords: Telmisartan; Ordered mesoporous alumina; Poorly water soluble drug; Oral bioavailability

Abbreviations

TEL: Telmisarton; ARB: Angiotensin II Receptor Antagonist; USFDA: United State Food and Drug Administration; BCS: Biopharmaceutical Classification System; OMA: Ordered Mesoporous Silica; EISA: Evaporation Induced Self Assembly; FTIR: Fourier Transform Infra-Red spectroscopy; KBr: Potassium Bromide; SEM: Scanning Electron Microscopy; TEM: Transmission Electron Microscopy; PXRD: Powder X- Ray Diffraction; Mpa: Mega Pascal; TGA: Thermo Gravimetric Analysis; IUPAC: International Union of Pure and Applied Chemistry.

Introduction

Many drugs exhibit poor water solubility hence low bioavailability; leading to limitations in potential formulation options and in some cases; resulting in drug candidates being rejected during the development process. Although several formulation approaches including solid dispersions [1]; emulsion based systems [2]; nanosizing [3] and cyclodextrin inclusion complexes [4] have led to promising in vitro results; mesoporous material based drug delivery systems have been investigated to enhance solubility [5] and thus improved bioavailability.

Mesoporous materials offer several attractive features for controlled release; such as a high adsorption capacity; the ability of the mesoporous channels to change the crystalline state of a drug to an amorphous one; the possibility of stabilizing loaded drugs within these pores and the ease of modifying the pore dimensions to control drug delivery kinetics. In the recent years; ordered mesoporous materials were investigated as materials for applications in many areas; such as catalysis; sorption; separation; drug delivery/controlled drug release [6].

Hypertension is an important public health challenge worldwide because of its high prevalence and concomitant increase in risk of disease [7]. In the year 2000; the world was estimated to have close to 1 billion people with hypertension and predicted an increase to 1.56 billion by 2025 [8]. The global economic burden of increased blood pressure was estimated to consume US$370 billion worldwide and 10% of healthcare expenditures [9].

Telmisartan (TEL) is an Angiotensin-II Receptor Antagonist (ARB) used in the management of hypertension [10] was approved by the US Food and Drug Administration (FDA) in 1998 [11]. It is indicated for the treatment of hypertension but Telmisartan’s dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease [12]. TEL is a BCS II drug with major drawback of its poor water solubility of 0.09 μg/ml and unsatisfactory bioavailability of 45% [13].

The present study was an approach to develop and evaluate Telmisartan (TEL) loaded Ordered Mesoporous Alumina (OMA) for enhanced solubility and dissolution of TEL.

Materials and Methods

Materials

The chemicals used in this work were of AR grade. Telmisartan and Pluronic F127 were obtained as a gift sample from Glennmark India Ltd; Nasik and Hi-media Laboratories; Mumbai respectively. Aluminium isopropoxide; ethanol and nitric acid were procured from Yarrowchem Pvt. Ltd. Mumbai.

Synthesis of ordered mesoporous alumina (OMA) scaffold

The OMA scaffold was synthesized by Evaporation Induced Self Assembly (EISA) mechanism. Approximately 0.75 g of Pluronic F127 was dissolved in 99.5% absolute ethanol and allowed to stir at room temperature for 1 h. Then; 1.0213 g of 98% aluminium isopropoxide was added; followed by 0.8 ml of 70% nitric acid. The total amount of ethanol was varied from 20 to 40 ml. The synthesis mixture was continuously stirred at room temperature for 12 h. Solvent evaporation was performed at 60°C in drying oven without stirring. After two days aging; the solution turned into a light yellow solid and further the resulting samples were calcined in muffle furnace by heating at 1°C /min to 70°C and then held at that temperature for 6 h [14].

Characterization of the ordered mesoporous alumina scaffold

Infrared spectroscopy: FT-IR spectroscopy used to determine the molecular interaction between excipients. Spectral analysis was carried out using FT-IR spectrophotometer (FT-IR 8400-S; Shimadzu; Japan); by the KBr pellet technique. The spectra were recorded at ambient temperature over a wave number range of 4000 to 400 cm-1. The samples were powdered and mixed with dry powdered potassium bromide. The powdered mixture was taken in sampler and scanned in FTIR spectrophotometer. A background scan was acquired before scanning the samples [15].

Scanning electron microscopy (SEM): The morphology of synthesized mesoporous alumina was examined by Scanning Electron Microscopy (SEM; JEOL; 5400; Tokyo; Japan). The samples were loaded on studs and applied fine gold coating with gold for 5 min at 10 mA ion current under a pressure of 0.1 Torr using ion sputter. The coated pellets were scanned and the micrographs were examined [16].

Transmission electron microscopy (TEM): The porous structure of sample was characterised by using Technai G2 20 (Philips; Holland). The sample was prepared on 300 mesh copper grid and scanned using TEM; operated at 200 kV [17].

Powder X-ray Diffraction (XRD): Powder X-ray Diffraction analysis was performed with a D5000 diffractometer (40 kV; 40 mA; Siemens/Bruker) using Cu-Ka radiation (l = 0.154 nm). About 500 mg sample was ground in a mortar and put on silicon sample holders with zero background prior to analysis [18,19].

Mercury porosimetry: The technique involves the intrusion of a non-wetting liquid (often mercury) at high pressure into a material through the use of a porosimeter. The pore size can be determined based on the external pressure needed to force the liquid into a pore against the opposing force of the liquid’s surface tension. The pore size; particle size distribution and surface area were determined by the mercury porosimetry technique by using the Pascal Mercury Porosimeter (Pascal 440; Thermo Electron Corporation; Italy). The intruded mercury volume was referred to the sample mass unit and was plotted versus applied pressure in Mpa. The sample was degassed in an oven at 120°C for 1 h [20].

Loading of telmisartan

The drug loading procedure involved a combination of adsorption equilibrium and solvent evaporation; which was developed in order to enhance the drug loading efficiency. The Telmisartan (TEL) was loaded in the OMA by the Solvent Impregnation Method. Briefly; Telmisartan (TEL) adsorption into Ordered Mesoporous Alumina (OMA) was carried out by soaking the OMA in an acetic acid solution of TEL (60 mg/ml). The mixture was then subjected to orbital shaking incubator. The loading was performed under ambient conditions (about 2°C) in closed containers to prevent evaporation of acetic acid during the loading period. Finally; the mixture was dried at 55°C under vacuum for 24 h [21]. The drug loaded sample was referred to as TEL: OMA.

Compatibility study of the TEL and OMA

After the successful drug loading in the OMA; there was need to determine the compatibility between the drug and the template material i.e. OMA. Molecular interaction between drug (TEL) and OMA was determined by FT-IR spectroscopy. Spectral analysis was carried out using FT-IR spectrophotometer (FT-IR 8400-S; Shimadzu; Japan); using the KBr pellet technique. The spectra were recorded at ambient temperature over a wave number range of 4000 to 400 cm-1. The samples were powdered and mixed with dry powdered potassium bromide. The powdered mixture was taken in sampler and scanned in FTIR spectrophotometer. A background scan was acquired before scanning the samples. The spectrum of the combination (TEL: OMA) was compared with the pure OMA and TEL [15].

Quantification of the drug

The Telmisartan loaded on the OMA was determined both by the UV spectrophotometry and Thermo Gravimetric Analysis (TGA). In UV spectroscopy the 20 mg of the TEL: OMA was solubilised in 100 ml of the phosphate buffer (pH 1.2) and kept under stirring for 24 h; then sonicated for 30 minutes. The sample was filtered through cellulose membrane and the amount of the drug was determined by UV spectrophotometer (UV1650; Shimadzu; Japan). The drug calibration curve was previously prepared in phosphate buffer (pH 1.2) (λmax=296; r=0.999). The Thermo Gravimetric Analysis was carried out by the thermal analyser (Pyris-1 TGA; Perkin Elmer) operating at heating rate 10°C /min and air flow of 30 ml/min [21].

Dissolution study

The drug release from OMA loaded sample was studied by using a USP Type II dissolution apparatus (Electrolab TDT-08L). The release study was carried out under sink conditions by using 900 ml 0.1 N HCl at 37°C at 100 rpm. At predetermined sampling intervals; 5 ml aliquots were taken and filtered through membrane filter. The removed sample was instantly replaced with an equal volume of fresh dissolution medium [22].

Results and Discussion

Characterization of the OMA scaffold

FT-IR study: As depicted in (Figure 1); the broad band at 3400 - 3500 cm-1 was assigned to the stretching vibration of the –OH group bonded to Al cation and peak at 1645 cm-1 corresponds to water of hydration. The shoulder band at 1404 cm-1 corresponds to -NO3 group from HNO3 added for acid treatment; while peak at 450-500 cm-1 is assigned to the bending vibrations of Al-O. The pattern of this bending band is an indication of alumina with gamma phase [15].